Micro Imaging Technology Updates the Status of the MIT 1000A Accompanying Family of Bacteria Identifying Software
November 08 2011 - 8:00AM
Marketwired
Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC) today
provided an update on the family of bacteria identifying software
that accompanies the MIT 1000A. The System, manufactured
exclusively for MIT by Hawthorne, CA-based OSI Optoelectronics,
Inc., is a stand-alone optically-based bacteria identification
system that uses proven principles of physics in conjunction with
proprietary PC-based software and is USB compliant. The MIT 1000A
can complete an identifying test in less than five (5) minutes and
with a material cost of pennies -- adding further credence to MIT's
claims of being able to annually save thousands of lives and tens
of millions of dollars in health care costs with their unique
technologies.
As explained by MIT's Chief Scientist, David Haavig, PhD: "In
the US, around 76 million cases of food borne illnesses, resulting
in 325,000 hospitalizations and 5,000 deaths, are estimated to
occur each year. The leading cause of these illnesses and deaths
are three main strains of bacteria: E. coli, Salmonella, and
Listeria. Rapid identification of these disease causing pathogens
in food is critical to the health and safety of all consumers."
Dr. Haavig further explained: "The AOAC Research Institute (AOAC
RI) awarded the Company, in June 2009, Performance Tested MethodsSM
(PTM) certification for the rapid identification of Listeria. The
AOAC RI provides an independent third-party evaluation of methods
and will award PTM certification to methods that demonstrate
performance levels equivalent or better than other bacteria
identifying methods. The MIT System underwent hundreds of
individual tests over an eighteen-month period to earn AOAC RI's
certification for the identification of Listeria; including
evaluations of hardware, software, ease of use, documentation,
ruggedness and accuracy."
Michael Brennan, MIT's Chairman, expanded on the Certification
status: "MIT will begin the process of earning Performance Tested
Methods Certification from the AOAC RI for the identification of E.
coli and Salmonella in December, 2011. This certification process
is far less difficult than the original Listeria certification. All
hardware, software, documentation, and test procedures are
identical to the Listeria certification process. The only items to
prepare are the E. coli and Salmonella Identifiers, or database
component, that should be concluded by early December."
About Micro Imaging Technology:
MIT is a California-based public company that has developed and
patented a Microbial Identification System that revolutionizes the
pathogenic bacteria diagnostic process. The System identifies
bacteria in minutes, not days, and at a significant per test cost
savings when compared to any other conventional method. Revenues
for all rapid testing methods exceed $5 billion annually -- with
food safety accounting for over $3.5 billion, which is expected to
surpass $4.7 billion by 2015 according to BCC Research. In
addition, the recently passed "New" U.S. Food Safety Bill is
expected to further accelerate the current annual growth rate of
6.6 percent.
The thoroughly green MIT System can currently identify over
twenty different species of bacteria without the use of chemicals,
reagents, dyes or DNA processing. The only additive is clean water
and a sample of the unknown bacteria. In addition to bacteria other
microbes can be easily added to the System's identifying
capabilities, including: protozoa, fungi, yeast and mold.
MIT, as mentioned in the foregoing, previously completed an
extensive evaluation by the AOAC RI which included rigorous
independent testing and thorough reviews by its expert examiners,
including the U.S. Department of Agriculture. This evaluation
process resulted in MIT being awarded the prestigious AOAC RI
Certificate of Performance Testing (Certificate No. 060901). The
AOAC RI Report is available from the Company. www.aoac.org
This release contains statements that are forward-looking in
nature. Statements that are predictive in nature, that depend upon
or refer to future events or conditions or that include words such
as "expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions are forward-looking
statements. These statements are made based upon information
available to the Company as of the date of this release, and we
assume no obligation to update any such forward-looking statements.
These statements are not guarantees of future performance and
actual results could differ materially from our current
expectations. Factors that could cause or contribute to such
differences include, but are not limited to dependence on
suppliers; short product life cycles and reductions in unit selling
prices; delays in development or shipment of new products; lack of
market acceptance of our new products or services; inability to
continue to develop competitive new products and services on a
timely basis; introduction of new products or services by major
competitors; our ability to attract and retain qualified employees;
inability to expand our operations to support increased growth; and
declining economic conditions, including a recession. These and
other factors and risks associated with our business are discussed
from time to time within our filings with the U.S. Securities and
Exchange Commission, reference MMTC: www.sec.gov.
CONTACT: Michael Brennan Chairman Email: Email Contact
Web Site: www.micro-imaging.com. Telephone: (805)
557-0614
Micro Imaging Technology (CE) (USOTC:MMTC)
Historical Stock Chart
From May 2024 to Jun 2024
Micro Imaging Technology (CE) (USOTC:MMTC)
Historical Stock Chart
From Jun 2023 to Jun 2024